...
首页> 外文期刊>Circulation. Cardiovascular interventions. >Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention Results From CHAMPION PHOENIX
【24h】

Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention Results From CHAMPION PHOENIX

机译:中央裁决确定额外的和影响预后重要的心肌梗死患者接受经皮冠状动脉干预的结果冠军凤凰

获取原文
获取原文并翻译 | 示例

摘要

Background: In the CHAMPION PHOENIX trial, cangrelor reduced the primary composite end point of death, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis at 48 hours. This study aimed to explore the impact of event adjudication and the prognostic importance of MI reported by a clinical events committee (CEC) or site investigators (SIs). Methods and Results: Data from the CHAMPION PHOENIX trial of patients undergoing elective or nonelective percutaneous coronary intervention were analyzed. A CEC systematically identified and adjudicated MI using predefined criteria, a computer algorithm to identify suspected events, and semilogarithmic plots to review biomarker changes. Thirty-day death was modeled using baseline characteristics. Of 10 942 patients, 462 (4.2%) patients had at least 1 MI by 48 hours identified by the CEC (207 [3.8%] cangrelor; 255 [4.7%] clopidogrel; odds ratio [OR] 0.80; 95% CI, 0.67-0.97; P=0.022), and 143 patients had at least 1 MI by 48 hours reported by the SI (60 [1.1%] cangrelor; 83 [1.5%] clopidogrel; OR, 0.72; 95% CI, 0.52-1.01; P=0.053). Of the 462 MIs identified by the CEC, 92 (20%) were reported by SI, and 370 (80%) were not. Of the 143 MI reported by the SI, 51 (36%) were not confirmed by CEC. All categories were associated with an increased adjusted risk for 30-day death (CEC: OR, 5.35; 95% CI, 2.56-11.2; PPPPP<0.001). Conclusions: In patients undergoing percutaneous coronary intervention, CEC procedures identified 3 times as many MIs as the SI reported. Compared with clopidogrel, cangrelor significantly reduced MIs identified by the CEC with a qualitatively similar relative risk reduction in MIs reported by the SI. MIs identified by CEC or reported by SI were independently associated with worse 30-day death. Central adjudication identified additional, prognostically important events.
机译:背景:在冠军凤凰试验中,cangrelor减少主要复合终点死亡,心肌梗死(MI),ischemia-driven血管再生,或支架在48小时内血栓形成。探索事件裁定和所带来的影响预后的重要性MI的报道临床事件委员会(CEC)或网站调查人员(SIs)。冠军凤凰试验的患者择期或nonelective经皮冠状动脉介入性治疗进行了分析。系统地识别和裁决MI使用预定义的标准,计算机算法识别可疑事件和半对数的情节审查生物标志物的变化。死亡是使用基线特征建模。10 942例,462例(4.2%)患者至少1米CEC(207 48小时内确认[3.8%] cangrelor;比[或]0.80;143名患者至少有1英里48小时报告的SI (60 [1.1%] cangrelor;氯吡格雷(1.5%);P = 0.053)。如果92人(20%)报告,370年(80%)不是。被CEC没有证实。与调整的风险增加有关30天的死亡(CEC:或者,5.35;PPPPP < 0.001)。经皮冠状动脉介入,CEC程序确认3倍的管理信息系统如果报道。显著降低MIs CEC确认定性相似的相对风险如果减少错误报告。被CEC或报道SI独立与差30天死亡。中央裁决确认另外,影响预后的重要事件。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号